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Abstract
Background: Isoflavones comprise a class of phytoestrogens that resemble human estrogen in chemical structure,
and have weak estrogenic effects. Because estrogen modulates sleep duration and quality, we hypothesized that
isoflavones would have a beneficial effect on sleep status in a way similar to estrogen. We conducted a cross-sectional
study to investigate the relationship between daily isoflavone intake and sleep status in Japanese subjects.
Methods: Our study included 1076 Japanese adults aged 20-78 years. Daily isoflavone intake was assessed using a brief
self-administered diet history questionnaire, and sleep was evaluated using a self-reported questionnaire.
Results: The prevalence of regular sleep duration (7–8 h/day) and sufficient sleep quality were 13.3 % and 56.2 %,
respectively. After adjusting for potential confounding factors, the odds ratios (95 % CIs) for optimal sleep duration (7–8 h)
when higher isoflavone intakes (Q2–Q4) were compared with low isoflavone intake (Q1) were Q2: 0.94 (0.53–1.56); Q3:
1.28 (0.73–2.24); and Q4: 1.84 (1.06–3.18) (p for trend = 0.013). In the final adjusted model, sufficient sleep quality across
categories of isoflavone intake was Q1: 1.00 (reference); Q2: 1.30 (0.91–1.84); Q3: 1.48 (1.03–2.12); and Q4: 1.78 (1.22–2.60);
(p for trend = 0.002).
Conclusion: Higher daily isoflavone intake was positively associated with optimal sleep duration and quality in a
Japanese population. This finding suggests that daily isoflavone intake may have a potentially beneficial effect on
sleep status.
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Introduction
Sleep is a homeostatic process that involves an active and
periodic biological state that is crucial to good physical and
mental health [1]. Sleep also has beneficial effects on stress
reactions and circadian rhythms [2]. However, sleep disor-
ders have increasingly become a major focus of public
health [3], and complaints concerning sleep problems and
symptoms of insomnia are common in older adults [4]. A
large prospective cohort study demonstrated that sleep
quality and sleep length (both short and prolonged sleep)
are related to increased mortality; in addition, risk of death
was lowest in those with an average of 7–8 h of sleep at
night [5]. Many studies have indicated that sleep complaints
(e.g., difficulties falling asleep) are associated with coronary
artery disease mortality in men [6]; furthermore, 7–8 h of
sleep per night can reduce the risks of coronary heart dis-
ease [7, 8], hypertension [9], diabetes [10], and obesity [11].
In recent years, the understanding of the effects of estro-
gen on brain function has increased considerably. Estrogen
acts on the brain primarily via the same neurotransmitters
that are involved in sleep regulation [12]. The majority of
research on hormone replacement therapy focuses on the
role of estrogen and its positive effects on sleep. Compared
with a placebo, estrogen replacement therapy has been
shown to alleviate insomnia [13]; other reported benefits
include improvements in falling asleep, diminished noctur-
nal restlessness, and fewer awakenings [14]. Isoflavones, a
class of phytoestrogens, share structural similarities with
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the mammalian hormone 17-β estradiol and have weak es-
trogenic effects. Isoflavones are relatively abundant in the
circulation of people and animals that consume soy. Many
studies have shown that isoflavones can bind to and
mediate transcription through estrogen receptors α and
β [15–17]. Several studies have also shown that in the
absence of estrogen, isoflavones have weak estrogenic
effects, while in the presence of estrogen, they may
exert an antagonistic effect [18, 19].
Therefore, it is conceivable that isoflavones may have po-
tentially beneficial effects on sleep status. To our know-
ledge, only two studies have examined the relationship
between isoflavones and sleep. Both determined that isofla-
vone treatment was effective on sleep disorders in post-
menopausal women [20, 21]. No studies, however, have
investigated the relationship between daily intake of isofla-
vone from food and sleep status in the general population.
Here, we conducted a cross-sectional study to investigate
the relationship between daily isoflavone intake and sleep
duration and quality in a Japanese population.
Methods
Study population
We used data from a prospective cohort study conducted
to investigate the risk factors of chronic diseases among
adult employees. The study was based on annual health ex-
aminations at the Sendai Oroshisho Center [22]. To stratify
for potential confounding variables, we added several as-
sessment parameters to the health examination: 1) ques-
tionnaires (details provided below), 2) physical performance
measurements (e.g., leg extension power and grip strength),
3) blood examination (e.g., adiponectin), and 4) daily phys-
ical activity (PA) assessment using a 3-dimensional acceler-
ometer [23].
The sample selection process is described in Fig. 1. In
total, 1833 individuals had previously undergone one of
two health examinations: lifestyle-related illnesses and
health examination A, which included blood examina-
tions, or health examination B, which did not include
blood examinations [22]. We invited all subjects who
had undergone the lifestyle-related illnesses and health
examination A to participate in the study (n = 1253). Of
those invited, 1154 agreed to participate and provided
informed consent for their data to be analyzed (re-
sponse rate 92.1 %). The Institutional Review Board of
the Tohoku University Graduate School of Medicine
approved the protocol for our study.
We excluded subjects without brief self-administered diet
history questionnaire (BDHQ) (n = 73), sleep (n = 4), or
Self-Rating Depression Scale (SDS) (n = 1) data. Therefore,
Fig. 1 Flow chart of the sample selection process
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the final study population comprised 1076 subjects (827
men and 249 women).
Assessment of dietary intake
Habitual dietary intake was assessed using the BDHQ
that included questions concerning the monthly food in-
take frequency of 75 food items, along with their speci-
fied serving sizes [24].
Isoflavone intake consisted of daidzein and genistein,
the major isoflavones found in soybeans. Typical isofla-
vone intake was measured using 3 soy foods that are rich
in isoflavones: natto, tofu, and fried tofu. The participants
indicated the mean frequency of consumption of these
foods over the past month by checking 1 of 7 frequency
categories, ranging from “almost never” to “2 or more
times/day.” The mean daily consumption of nutrients was
calculated using an ad hoc computer program developed
to analyze the questionnaire. The Japanese food compos-
ition tables (5th edition) were used as the nutrient data-
base. Energy-adjusted values by the density method
(/1000 kcal) were used for all nutrients. We summarized
the quantity of daily isoflavone intake in quartiles as fol-
lows, Q1: 0–10.96 mg/1000 kcal/day; Q2: 10.97–
17.99 mg/1000 kcal/day; Q3: 18.00–26.73 mg/1000 kcal/
day; and Q4: 26.74–83.06 mg/1000 kcal/day.
Assessment of sleep
We assessed sleep using a standard questionnaire that in-
cluded sleep-related questions. Information on sleep dur-
ation was obtained by asking, “How many hours do you
usually sleep per day?” Six response alternatives were pro-
vided: < 5 h, 5–6 h, 6–7 h, 7–8 h, 8–9 h, and ≥ 9 h. Sleep
duration was then categorized into 2 classes: 7–8 h; and <
7 h or ≥ 8 h. Information on sleep quality was obtained by
asking “Do you usually feel refreshed after sleep?” Possible
answers were “yes” and “no.” The use of hypnotics was
assessed in the question “Have you used hypnotic drugs in
the past month?” Possible answers were “yes” and “no.”
Assessment of other variables
Depressive symptoms were assessed according to the
Japanese version of the SDS [25]. An SDS score ≥ 50 was
defined as the cut-off point indicating relatively mild or
severe depressive symptoms [26]. Blood pressure was
measured twice, on the upper left arm, with an automatic
device (YAMASU605P; Kenzmedico Co., Ltd., Saitama,
Japan) after 5 min of rest in the sitting position. The mean
of the 2 measurements was used for analyses.
Blood samples were collected in siliconized vacuum
glass tubes containing sodium fluoride. Fasting blood glu-
cose concentrations were measured using enzymatic
methods (Eerotec Co., Ltd., Tokyo, Japan). The concentra-
tions of triglycerides, low-density lipoprotein cholesterol,
and high-density lipoprotein cholesterol were measured
using enzymatic methods with the appropriate kits
(Sekisui Medical Co., Ltd., Tokyo, Japan).
Body mass index (BMI) was calculated as weight/
height2 (kg/m2). The criteria from American Heart As-
sociation scientific statements were used to define meta-
bolic syndrome. Participants were considered to have
metabolic syndrome if they presented with ≥ 3 of the
following risk factors: (1) abdominal obesity: waist cir-
cumference ≥ 90 cm (for men) or ≥ 80 cm (for women);
(2) hypertension: systolic BP ≥ 130 mmHg or diastolic
BP ≥85 mmHg, or anti-hypertensive drug treatment; (3)
elevated triglycerides: serum triglycerides ≥ 150 mg/dL
or drug treatment for elevated triglycerides; (4) reduced
HDL-C: HDL-C < 40 mg/dL (for men) or < 50 mg/dL
(for women), or the use of medications for reduced
HDL-C; and (5) hyperglycemia: fasting plasma glu-
cose ≥ 100 mg/dL or drug treatment for elevated glu-
cose. Level of education was determined as the last
qualification attained, and was subsequently divided into 2
categories: < college or ≥ college. Subjects were asked
whether they had a history of physical illness or if they
were currently taking any medication; answers were given
as “yes” or “no.” Information on age, sex, smoking status,
and occupation was obtained using a questionnaire sur-
vey. Daily PA was determined using the International
Physical Activity Questionnaire (IPAQ), and total daily PA
was calculated as follows: METs × h/week [27]. PA was
then divided into two categories, high and low, matched
for number of individuals.
Statistical analysis
Descriptive data are presented as the means (95 % CIs)
or as percentages. Sleep duration and sleep quality were
used as dependent variables and isoflavone intake cat-
egories (Q1–Q4) were used as independent variables.
The differences in variables between the isoflavone in-
take categories were examined using analysis of variance
for continuous variables or the χ2 test for variables of
proportion. Multivariate logistic analysis was used to de-
termine the relationships between isoflavone intake cat-
egories and sleep duration and quality, and to adjust for
potentially confounding variables. Model 1 was adjusted
for age, sex, and BMI. Model 2 was adjusted for those
variables in Model 1, along with intake of vitamins B12,
C, and D, and coffee consumption. Model 3 was ad-
justed for those variables in Model 2, along with smok-
ing and drinking habits, PA, level of education, SDS
score, metabolic syndrome, high-sensitivity C-reactive
protein (hsCRP), occupation, and hypnotic drug use.
The final multivariate logistic analysis was performed
with the forced entry of all factors considered as poten-
tial covariates. All p-values for linear trends were calcu-
lated using the isoflavone intake categories (Q1, Q2, Q3,
Q4). The interactions between isoflavone intake and all
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confounding variables for sleep duration and sleep qual-
ity were tested through the addition of the cross-product
terms to the regression model. All statistical analyses
were performed using the SPSS/PC statistical software
version 17.0 for Windows (SPSS, Inc., Chicago, IL); the
significance level was set at p < 0.05.
Results
Data were obtained from 1076 subjects; 143 (13.3 %)
subjects were classified as having normal sleep duration
(7–8 h), and 605 (56.2 %) subjects were classified as suf-
ficient sleepers with regard to sleep quality. Baseline
characteristics, according to isoflavone intake categories,
are presented in Table 1. The proportions of subjects
who were ex-smokers or nonsmokers, had high PA, were
elderly, and were significantly high across the isoflavone
intake quartiles (p for trend p < 0.001; variables: p <
0.048, p < 0.001, and p = 0.016, respectively). The mean
dietary intakes for all items, except coffee consumption,
was significantly high across the categories of isoflavone
intake (p for trend < 0.001). The mean coffee consump-
tion and proportions of subjects who were current
smokers were significantly lower across categories of iso-
flavone intake (p for trend = 0.028; variable: p < 0.001).
The relationships between categories of isoflavone in-
take and sleep duration are shown in Table 2. After
adjusting for age, sex, and BMI in Model 1, the odds ra-
tios (ORs) for sleep duration increased across categories
of isoflavone intake. The ORs for sleep duration across
isoflavone intake categories Q1, Q2, Q3, and Q4 were
1.00 (reference), 0.93 (95 % CI, 0.54–1.61), 1.12 (95 %
CI, 0.66–1.92), and 1.64 (95 % CI, 0.99–2.74), respect-
ively (p for trend = 0.033). After adjusting for dietary in-
take in Model 2, the ORs for sleep duration across
isoflavone intake categories Q1, Q2, Q3, and Q4 were
1.00 (reference), 0.98 (95 % CI, 0.56–1.70), 1.24 (95 %
CI, 0.72–2.14) and 1.92 (95 % CI, 1.13–3.27), respect-
ively (p for trend = 0.008). A similar association was
Table 1 Subject characteristics according to categories of daily isoflavone intake
Categories of isoflavone intakea p for
trendbQ1 (Low) Q2 Q3 Q4 (High)
n 269 269 269 269
Sex (male; %) 75.8 79.6 77.3 74.7 0.628
Age (years) 43.3 (42.0, 44.5)c 45.5 (44.3, 46.7) 46.9 (45.7, 48.2) 49.6 (48.4, 50.9) <0.001
BMI (kg/m2) 23.1 (22.7, 23.6) 23.2 (22.7, 23.6) 23.5 (23.1, 24.0) 22.9 (22.5, 23.3) 0.672
Dietary intake
Vitamin B12 (μg/1000 kcal) 4.0 (3.7, 4.3) 4.6 (4.3, 4.9) 4.9 (4.6, 5.2) 4.9 (4.6, 5.2) <0.001
Vitamin C (mg/1000 kcal) 42.3 (39.4, 45.1) 48.1 (45.2, 50.9) 52.9 (50.0, 55.7) 60.2 (57.3, 63.0) <0.001
Vitamin D (mg/1000 kcal) 5.0 (4.6, 5.5) 5.9 (5.4, 6.4) 6.8 (6.3, 7.3) 7.1 (6.6, 7.6) <0.001
Coffee consumption (g/d) 254.6 (231.0, 278.2) 236.7 (213.1, 260.3) 247.7 (224.1, 271.3) 211.4 (187.7, 235.0) 0.028
PA (high; %) 47.6 48.0 45.0 59.5 0.016
Smoking status (%)
Current smoker 55.3 46.9 42.3 36.1 <0.001
Ex-smoker 8.2 12.2 15.0 14.5 0.016
Nonsmoker 34.6 39.8 45.7 51.3 <0.001
Drinking status (%)
Drinking everyday 28.3 30.5 26.0 25.3 0.272
Drinking occasionally 48.0 49.8 49.8 53.5 0.220
Nondrinker 23.8 19.7 24.2 21.2 0.768
Education level≥ college (%) 76.6 68.0 71.0 73.6 0.626
Occupation (desk work; %) 45.9 43.9 39.9 50.8 0.439
Metabolic syndrome (%) 28.3 27.5 33.8 29.0 0.493
Depression (%) 14.1 14.5 11.5 13.8 0.661
hsCRP (mg/L) 0.1 (0.7, 1.4) 1.1 (0.7, 1.4) 1.1 (0.8, 1.5) 0.6 (0.3, 1.0) 0.172
Hypnotic drug use (%) 4.8 3.3 2.2 3.0 0.173
aBMI body mass index, PA physical activity, hsCRP high-sensitivity C-reactive protein
bObtained using analysis of variance for continuous variables and χ2 test for proportional variables
cMean (95 % CI) (all such values)
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observed between sleep duration and isoflavone intake
in Model 3 (p for trend = 0.013).
The relationships between categories of isoflavone in-
take and sleep quality are shown in Table 3. After adjust-
ing for age, sex, and BMI in Model 1, the ORs for sleep
quality across isoflavone intake categories Q1, Q2, Q3,
and Q4 were 1.00 (reference), 1.33 (95 % CI, 0.94–1.87),
1.52 (95 % CI, 1.07–2.14), and 1.91 (95 % CI, 1.34–2.72),
respectively (p for trend = 0.000). In Model 2, the ORs
for sleep quality across isoflavone intake categories Q1,
Q2, Q3, and Q4 were 1.00 (reference), 1.31 (95 % CI,
0.93–1.86), 1.49 (95 % CI, 1.05–2.12), and 1.85 (95 % CI,
1.28–2.67), respectively (p for trend = 0.001). A similar
association was observed between sleep duration and
isoflavone intake in Model 3 (p for trend = 0.002). The
prevalence of either 7–8 h of sleep duration or better
sleep quality was higher for subjects who consumed
26.74–83.06 mg/1000 kcal/d isoflavone (Q4) than for
those who consumed 0–10.96 mg/1000 kcal/d isoflavone
(Q1) in all models except Model 1 of the relationship be-
tween isoflavone intake and sleep duration (Bonferroni
corrected p < 0.05). In addition, there was no significant
interaction between isoflavone intake and sex, either for
sleep duration or for sleep quality (p for interaction =
0.74 and 0.36, respectively). Likewise, there was no sig-
nificant interaction between isoflavone intake and other
confounding variables in the final models.
Discussion
The present study examined the relationships between
daily isoflavone intake and sleep duration and quality. Our
results suggest that high daily isoflavone intake from food
is significantly related to optimal sleep duration (7–8 h)
and better sleep quality. In addition, this relationship was
not changed when adjusted for a number of potentially
confounding variables, such as age, sex, BMI, total energy
intake, coffee or vitamin consumption, smoking and drink-
ing habits, level of education, occupation, depression,
hsCRP level, or hypnotic drug use.
A previous study of 169 postmenopausal women showed
that isoflavone treatment was effective in improving quality
of life and decreasing climacteric symptoms, including sleep
disturbance [21]. In addition, a randomized controlled trial
study on postmenopausal women with insomnia indicated
that sleep efficiency was significantly increased in the isofla-
vone treatment group compared to the placebo group [20].
These findings are consistent with those of the current
study, which demonstrated a positive relationship between
Table 2 Adjusted relationship between daily intake of isoflavone and sleep duration
Categories of isoflavone intake p for
trendaQ1 (Low) Q2 Q3 Q4 (High)
No. of subjects 269 269 269 269
Sleep duration of 7–8 h/day (No.) 29 29 34 51
Model 1b 1.00 0.93 (0.54, 1.61)c 1.12 (0.66, 1.92) 1.64 (0.99, 2.74) 0.033
Model 2d 1.00 0.98 (0.56, 1.70) 1.24 (0.72, 2.14) 1.92 (1.13, 3.27)e 0.008
Model 3f 1.00 0.94 (0.55, 1.65) 1.28 (0.73, 2.24) 1.84 (1.06, 3.18)e 0.013
aObtained by multiple logistic regression analysis
bAdjusted for age, sex, and body mass index
cAdjusted odds ratio (95 % CI) (all such values)
dFurther adjusted for intake of vitamins B12, C, and D; and coffee consumption
eSignificantly different than category Q1, p < 0.05 (Bonferroni corrected)
fFurther adjusted for smoking, drinking habits, physical activity, depressive symptoms, metabolic syndrome; high-sensitivity C-reactive protein level, education
level, occupation, and hypnotic drug use
Table 3 Adjusted relationship between daily intake of isoflavone and sleep quality
Categories of isoflavone intake p for
trendaQ1 (Low) Q2 Q3 Q4 (High)
No. of subjects 269 269 269 269
No. with sufficient sleep 126 148 157 174
Model 1b 1.00 1.33 (0.94, 1.87)c 1.52 (1.07, 2.14)d 1.91 (1.34, 2.72)d <0.001
Model 2e 1.00 1.31 (0.93, 1.86) 1.49 (1.05, 2.12)d 1.85 (1.28, 2.67)d 0.001
Model 3f 1.00 1.30 (0.91, 1.84) 1.48 (1.03, 2.12)d 1.78 (1.22, 2.60)d 0.002
aObtained by multiple logistic regression analysis
bAdjusted for age, sex, and body mass index
cAdjusted odds ratio (95 % CI) (all such values)
dSignificantly different than category Q1, p < 0.05 (Bonferroni corrected)
eFurther adjusted for intake of vitamins B12, C, and D; and coffee consumption
fFurther adjusted for smoking, drinking habits, physical activity, depressive symptoms, metabolic syndrome, high-sensitivity C-reactive protein level, education
level, occupation, and hypnotic drug use
Cui et al. Nutrition Journal  (2015) 14:127 Page 5 of 7
isoflavone intake and sleep quality. This consistency also
suggests that there is a positive relationship between isofla-
vone intake and sleep quality, not only in postmenopausal
women, but also in the general population.
Although the biological mechanisms involved in the re-
lationship between isoflavone and sleep are unknown,
there are some possible explanations. First, it has been de-
termined that estrogen may affect some neurotransmitters
in the brain, such as serotonin [28]. Serotonin is an im-
portant neurotransmitter, one function of which is to
regulate the sleep-wake cycle [29]. Thus, it is possible that
isoflavone acts as an estrogen mimetic to affect serotoner-
gic function and regulate the sleep-wake cycle. Second,
previous studies indicate that estrogen replacement ther-
apy improves sleep quality [14, 30]. It is conceivable that
isoflavones may also have beneficial effects on sleep qual-
ity in a similar way to estrogen, due to the estrogenic ef-
fects of isoflavone. Additionally, it has been shown that
isoflavone intake has beneficial effects on cognitive func-
tion [31, 32] and endocrine such as IGF-1 [33]. Since cog-
nitive function is positively related with sleep quality [34],
and high plasma IGF-1 level is associated with increased
delta sleep [35], we considered that isoflavone might also
affect sleep by cognitive function or IGF-1. In addition, a
previous study indicated that soy isoflavone supplementa-
tion decreased levels of oxidative stress in both men and
women aged 22-56 years [36]. Further, oxidative stress
may be a risk factor for poor sleep quality because an
interventional study showed that anti-oxidant intake can
improve the quality of sleep in sleep apnea syndrome pa-
tients [37]. Hence, we considered that antioxidant effects
of isoflavone may also be a possible mechanism under-
lying the association between isoflavone intake and sleep
status in present study.
Some limitations of this study should be discussed. First,
our study does not exclude the possibility that isoflavone
intake would not be associated with sleep quality and dur-
ation in premenopausal women who have higher level of
estrogen. However, we could not examine the association
of isoflavone intake with sleep duration and quality in pre-
menopausal women because of the insufficient sample
size. Although statistical adjustment for sex in the multi-
variate analysis showed a general association of isoflavone
intake and sleep duration and quality, further study is ne-
cessary to examine whether the weak estrogen mimetic
action of isoflavone could modify or improve the sleep
duration and quality in premenopausal women. Second,
because this study was a cross-sectional study, we could
not conclude whether high isoflavone intake improved
sleep duration and sleep quality, or whether sleep duration
and sleep quality led to an increase in isoflavone intake.
Third, we collected dietary data using a self-administered
diet history questionnaire. Although this questionnaire
has been validated and energy-adjusted values of dietary
intake were used to minimize the effect of measurement
errors derived from self-reported dietary data, real dietary
habits were not observed. Finally, we adjusted for a num-
ber of confounding factors, but we cannot exclude the
possibility that sleep duration and sleep quality are af-
fected by other dietary habits that correlate with the habit-
ual intake of isoflavone.
Conclusions
In the present study, higher daily isoflavone intake from
food was significantly associated with better sleep duration
and higher sleep quality in a Japanese population, even
after adjusting for potentially confounding factors. This
suggests that the daily intake of isoflavones in food may
have a potentially beneficial effect on sleep duration and
quality, Prospective or interventional studies are required
to clarify the causality.
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